1 **Bone marrow adipose tissue is a unique adipose subtype with distinct roles in**
2 **systemic glucose homeostasis**
3
4 ***Running Title:*** Marrow adipose tissue is a distinct, major subtype of adipose tissue
5

6 Karla J. Suchacki[1], Adriana A.S. Tavares[1], Domenico Mattiucci[1,2], Erica L. Scheller[3],
7 Giorgos Papanastasiou[4], Calum Gray[4], Matthew C. Sinton[1], Lynne E. Ramage[1], Wendy A.
8 McDougald[1], Andrea Lovdel[1], Richard J. Sulston[1], Benjamin J. Thomas[1], Bonnie M.
9 Nicholson[1], Amanda J. Drake[1], Carlos J. Alcaide-Corral[1], Diana Said[1], Antonella Poloni[2],
10 Saverio Cinti[2,5], Gavin J. MacPherson[6], Marc R. Dweck[1], Jack P.M. Andrews[1], Michelle C.
11 Williams[1], Robert J. Wallace[7], Edwin J.R. van Beek[4], Ormond A. MacDougald[8], Nicholas M.
12 Morton[1], Roland H. Stimson[1] and William P. Cawthorn[1*].
13

14 [1]University/BHF Centre for Cardiovascular Science, University of Edinburgh, The Queen's
15 Medical Research Institute, Edinburgh BioQuarter, 47 Little France Crescent, Edinburgh,
16 EH16 4TJ, Scotland, UK. [2]Dipartimento di Scienze Cliniche e Molecolari, Clinica di
17 Ematologia, Università Politecnica delle Marche, Ancona, Italy. [3]Division of Bone and
18 Mineral Diseases, Department of Medicine, Washington University, St. Louis, MO, USA.
19 [4]Edinburgh Imaging, University of Edinburgh, UK. [5]Dipartimento di Medicina Sperimentale
20 e Clinica, Center of Obesity, Università Politecnica delle Marche, Ancona, Italy. [6]Department
21 of Orthopaedic Surgery, Royal Infirmary Edinburgh, UK. [7]Department of Orthopaedics, The
22 University of Edinburgh, UK. [8]Department of Molecular & Integrative Physiology, University
23 of Michigan, Ann Arbor, MI, USA.
24
25

26 ***Correspondence to***: William Cawthorn, University/BHF Centre for Cardiovascular
27 Science, The Queen's Medical Research Institute, Edinburgh BioQuarter, 47 Little France
28 Crescent, Edinburgh, EH16 4TJ. W.Cawthorn@ed.ac.uk
29
30
31
32 **Keywords:**
33 Bone marrow adipose tissue, bone marrow adipocytes, white adipose tissue, brown adipose
34 tissue, beige adipose tissue, PET/CT, glucose homeostasis, insulin, cold exposure, bone

HIGHLIGHTS

- Bone marrow adipose tissue (BMAT) is molecularly distinct to other adipose subtypes.
- BMAT is less insulin responsive than WAT and, unlike BAT, is not cold-responsive.
- Human BMAT has greater basal glucose uptake than axial bone or subcutaneous WAT.
- We establish a PET/CT method for BMAT localisation and functional analysis *in vivo.*

SUMMARY

Bone marrow adipose tissue (BMAT) represents >10% of total adipose mass, yet unlike white or brown adipose tissues (WAT or BAT), its role in systemic metabolism remains unclear. Using transcriptomics, we reveal that BMAT is molecularly distinct to WAT but is not enriched for brown or beige adipocyte markers. Instead, pathway analysis indicated altered glucose metabolism and decreased insulin responsiveness in BMAT. We therefore tested these functions in mice and humans using positron emission tomography–computed tomography (PET/CT) with ^{18}F-fluorodeoxyglucose, including establishing a new method for BMAT identification from clinical CT scans. This revealed that BMAT resists insulin- and cold-stimulated glucose uptake and is thus functionally distinct to WAT and BAT. However, BMAT displayed greater basal glucose uptake than axial bones or subcutaneous WAT, underscoring its potential to influence systemic glucose homeostasis. These PET/CT studies are the first to characterise BMAT function *in vivo* and identify BMAT as a distinct, major subtype of adipose tissue.

INTRODUCTION

Adipose tissue plays a fundamental role in systemic energy homeostasis. In mammals it is typically classified into two major subtypes: white adipose tissue (WAT), which stores and releases energy and has diverse endocrine functions; and brown adipose tissue (BAT), which mediates adaptive thermogenesis (Cinti, 2018). Cold exposure and other stimuli also cause the emergence of brown-like adipocytes within WAT, typically referred to as "beige" adipocytes (Cinti, 2018). White, brown and beige adipocytes have attracted extensive research interest, owing largely to their roles and potential as therapeutic targets in metabolic diseases.

Adipocytes are also a major cell type within the bone marrow (BM), accounting for up to 70% of BM volume. Indeed, this BM adipose tissue (BMAT) can represent over 10% of total adipose tissue mass in healthy adults (Cawthorn et al., 2014). BMAT further accumulates in diverse physiological and clinical conditions, including aging, obesity, type 2 diabetes and osteoporosis, as well as therapeutic contexts such as radiotherapy or glucocorticoid treatment. Strikingly, BMAT also increases in states of caloric restriction (Scheller et al., 2016). These observations suggest that BMAT is distinct to WAT and BAT and might impact the pathogenesis of diverse diseases. However, unlike WAT and BAT, the role of BMAT in systemic energy homeostasis remains poorly understood.

The metabolic importance of WAT is highlighted in situations of both WAT excess (obesity) and deficiency (lipodystrophy), each of which leads to systemic metabolic dysfunction (Cinti, 2018). This largely reflects the key role of WAT as an insulin target tissue. Adipocyte-specific ablation of the insulin receptor in mice causes insulin resistance, glucose intolerance and dyslipidaemia (Qiang et al., 2016; Sakaguchi et al., 2017). Similar effects result from adipocytic deletion of *Slc2a4* (Glut4), the insulin-sensitive glucose transporter (Abel et al., 2001). Conversely, adipocyte-specific overexpression of *Slc2a4* reverses insulin resistance and diabetes in mice predisposed to diabetes (Carvalho et al., 2005). Thus, insulin-stimulated glucose uptake is fundamental to WAT's role in systemic metabolic homeostasis.

In contrast to WAT, the defining function of BAT is in mediating adaptive thermogenesis via uncoupled respiration. This is driven by mitochondria expressing uncoupling protein-1 (UCP1), which are abundant in brown adipocytes. Cold exposure is the classical stimulator of BAT activity: cold-induced glucose uptake is a hallmark of BAT activation and can be quantified *in vivo* using positron emission tomography–computed tomography (PET/CT) with ^{18}F-fluorodeoxyglucose (^{18}F-FDG) (Cinti, 2018; Ramage et al., 2016a). Cold exposure or chronic sympathetic stimulation exert similar effects on beige adipocytes, and activation of brown or beige adipocytes can enhance energy expenditure (Cinti, 2018). Consequently, the past decade has seen extensive interest in activating BAT, or promoting beiging of WAT, to treat metabolic disease (Cinti, 2018).

Compared to WAT and BAT, study of BMAT has been relatively limited. However, given its abundance and clinical potential (Scheller et al., 2016), BMAT is now attracting increasing attention, with several studies beginning to investigate its metabolic properties. BM adipocytes (BMAds) have been proposed to exist in two broad subtypes: 'constitutive' BMAds (cBMAds) appear as contiguous groups of adipocytes that predominate at distal skeletal sites, whereas 'regulated' BMAds (rBMAds) occur interspersed with the haematopoietic BM in the proximal and axial skeleton (Craft et al., 2018). Both subtypes are morphologically similar to white adipocytes, with large unilocular lipid droplets; however, their lipid content differs, with cBMAds having a greater proportion of unsaturated fatty acids than rBMAds or white adipocytes (Scheller et al., 2016). Like white adipocytes, BMAds also

produce adipokines such as leptin and adiponectin (Sulston and Cawthorn, 2016) and can release free fatty acids in response to lipolytic stimuli, albeit to a lesser extent than WAT (Scheller et al., 2018; Tran et al., 1981). This lipolysis resistance is more pronounced for rBMAds, underscoring the functional differences in BMAd subtypes.

Despite these advances in understanding of BMAT lipid metabolism, its insulin responsiveness and role in systemic glucose homeostasis is poorly understood. PET/CT studies have demonstrated glucose uptake into whole bones or BM of animal models and humans (Huovinen et al., 2016; Huovinen et al., 2014; Nishio et al., 2012; Zoch et al., 2016), but uptake specifically into BMAT has not previously been examined. Whether BMAT is BAT- or beige-like is also debated (Scheller et al., 2016). UCP-1 positive adipocytes have been noted in vertebral BM of a young mouse (Nishio et al., 2012) and as an incidental finding in one clinical case study (Chapman and Vega, 2017), but most studies find very low skeletal UCP-1 expression (Krings et al., 2012; Sulston et al., 2016). It has been suggested that BMAT is BAT-like, albeit based only on transcript expression from whole bones (Krings et al., 2012). Notably, no studies have fully investigated if BMAT has properties of BAT or beige fat *in vivo.* Together, it remains unclear if BMAT performs metabolic functions similar to WAT, BAT or beige adipose tissue.

Herein, we used transcriptomic analysis and ^{18}F-FDG PET/CT to address these fundamental gaps in knowledge and thereby determine if, *in vivo,* BMAT has metabolic functions of WAT or BAT. Our studies in animal models and humans demonstrate that BMAT is transcriptionally and functionally distinct to WAT, BAT and beige adipose tissue, identifying BMAT as a unique class of adipose tissue. We show that BMAT has greater basal glucose uptake than WAT and establish methods for BMAT characterisation by PET/CT. Together, this knowledge underscores the potential for BMAT to influence metabolic homeostasis and sets a foundation for future research to reveal further roles of BMAT in normal physiology and disease.

RESULTS

BMAT is transcriptionally distinct to WAT, BAT and beige adipose tissues

The functional hallmarks of WAT, BAT and beige adipose tissue are reflected on a molecular level, with each class having distinct transcriptomic profiles and characteristic marker genes (Rosell et al., 2014; Svensson et al., 2011; Wu et al., 2012). Thus, to test if BMAT has distinct metabolic functions, we first compared the transcriptomes of whole BMAT and WAT from two cohorts of rabbits. Principle component analysis of both cohorts identified BMAT as a distinct depot compared to gonadal WAT (gWAT) and inguinal WAT (iWAT) (Fig. 1A); however, BMAT from either rabbit cohort was not uniformly enriched for markers of brown or beige adipocytes (Fig. 1B, S1A): although *SLC27A2* was significantly higher in BMAT than WAT from both cohorts, and *PPARGC1A* in BMAT from cohort 1, several other brown and/or beige markers were more highly expressed in WAT, while most such markers were not differentially expressed between BMAT and WAT in either cohort (Fig. 1B, S1A). Thus, the transcriptomic distinction with WAT is not a result of BMAT being more brown- or beige-like. Instead, gene set enrichment analysis (GSEA) highlighted the potential for BMAT to have altered glucose metabolism and decreased insulin responsiveness compared to WAT (Fig. 1C,1D, S1B).

To determine if similar differences occur in humans, we next analysed the transcriptomes of adipocytes isolated from human femoral BMAT and subcutaneous WAT, which our previous analyses revealed to be globally distinct (Mattiucci et al., 2018). Consistent with our findings in rabbits, human BMAds were not enriched for brown or beige markers and had decreased expression of genes relating to glucose metabolism and insulin responsiveness (Fig. 1E, S2A, S2B). To further address this we next pursued targeted analysis of adipocytes isolated from BM and WAT of a second cohort of subjects; we also isolated adipocytes from trabecular bone (Bone Ads) to assess potential site-specific differences in BMAd function (Craft et al., 2018). Adipocyte purity was confirmed histologically (data not shown) and by qPCR (Fig. S2C). *In situ,* these BM and bone adipocytes resembled unilocular white adipocytes (Fig. 1F); however, qPCR revealed significant differences in transcript expression of *INSR, IRS1, IRS2, SLC2A4, SLC2A1* and *SLC2A3* between WAT adipocytes and those from BM or bone (Fig. 1G). Notably, compared to white adipocytes, each BMAd subtype had decreased *SLC2A4* and increased *SLC2A1* and *SLC2A3,* suggesting that BMAds may have higher basal glucose uptake that is less insulin responsive. In contrast, there were no differences in expression of *UCP1,* and most other brown or beige adipocyte markers were not enriched in either BMAd subtype (Fig. 1G, S2D).

Taken together, these data demonstrate that BMAds in animal models and humans are transcriptionally distinct to white, brown and beige adipocytes, and suggest altered roles in systemic glucose homeostasis and insulin responsiveness.

Insulin treatment in mice does not induce glucose uptake in BMAT

To test the metabolic functions of BMAT *in vivo* we used ^{18}F-FDG PET/CT in mice to determine if, like WAT, BMAT is insulin-responsive. As expected, insulin decreased blood glucose (Fig. 2A) and increased ^{18}F-FDG uptake in the heart, iWAT and gWAT (Fig. 2B, C and F). To assess ^{18}F-FDG uptake separately within bone and BMAT, we first applied thresholding to the PET/CT data to separate bone from BM based on their different tissue densities *(data not shown).* This revealed that insulin significantly increased ^{18}F-FDG uptake in femoral bone, whereas humoral bone uptake decreased; uptake in proximal or distal tibial bone was unaffected (Fig. 2F). To assess BMAT-specific ^{18}F-FDG uptake we took advantage of the regional differences in BMAT content around the mouse skeleton. Thus, adipocytes comprise only a small percentage of total BM volume of humeri, femurs and

190 proximal tibiae, but predominate in distal tibiae (Fig. 2E). To address the contribution of
191 BMAT to skeletal ^{18}F-FDG uptake, we therefore quantified ^{18}F-FDG in a bone-region-specific
192 manner to distinguish between areas of low BMAT (humerus, femur, proximal tibia) and high
193 BMAT (distal tibia). This revealed that insulin did not significantly affect glucose uptake in
194 any of the BM regions analysed (Fig. 2F). Thus, compared to WAT, BM and BMAT resist
195 insulin-stimulated glucose uptake.

196

Cold exposure in mice does not induce glucose uptake or beiging in BMAT

198 To test if BMAT is BAT- or beige-like *in vivo*, we next analysed ^{18}F-FDG uptake following
199 acute or chronic cold exposure in mice (Fig. S3A). Acute (4 h) or chronic cold (72 h)
200 increased energy expenditure without causing weight loss or hypoglycaemia (Fig. S3B-D),
201 likely due to increased food consumption in chronic cold mice (Fig. S3E). BAT ^{18}F-FDG
202 uptake increased after either duration of cold (Fig. 3A-C). Chronic cold also increased iWAT
203 ^{18}F-FDG uptake, suggesting beiging of this depot (Fig. 3C). However, neither acute nor
204 chronic cold exposure increased ^{18}F-FDG uptake into bone or BM (Fig. 3B). Indeed, cold
205 exposure decreased ^{18}F-FDG uptake into distal tibial BMAT, highlighting fundamental
206 differences with iWAT and BAT. Cold exposure also decreased BAT lipid content and
207 promoted beiging of iWAT, as indicated by formation of multilocular adipocytes, but these
208 effects did not occur in BMAT (Fig. 3D). Consistent with this, cold exposure induced brown
209 and beige transcripts in BAT and iWAT, but not within bone (Fig. 3E-G, S3F-H). Housing
210 control mice at room temperature (22 ºC) might have caused a mild cold stress, preventing
211 detection of further beiging at 4 ºC; however, even when compared to mice at
212 thermoneutrality (28 ºC), cold exposure did not induce a beiging response within bones (Fig.
213 S3I). These results show that, *in vivo*, BMAT is functionally distinct to brown and beige
214 adipose tissues.

215

CT-based identification of BMAT in humans

217 We next tested if these distinct metabolic properties extend to BMAT in humans. First, we
218 established a method to identify BMAT from clinical PET/CT scans. To determine Hounsfield
219 Units (HU) for BMAT, we identified BMAT-rich and BMAT-deficient BM regions by magnetic
220 resonance imaging (MRI). This revealed that sternal BM is BMAT-enriched while vertebral
221 BM is BMAT-deficient (Fig. 4A); WAT was also analysed as an adipose-rich control region.
222 We then co-registered the MRI data with paired CT scans of the same subjects (Fig. 4A).
223 This revealed a distinct HU distribution for BMAT-rich sternal BM, intermediate between
224 WAT and red marrow (RM) of BMAT-deficient vertebrae (Fig. 4B).

225

226 Using these distinct HU distributions, we generated a receiver operating characteristic
227 (ROC) curve to identify optimal diagnostic HU thresholds to distinguish BMAT from RM (Fig.
228 S4A). This revealed that BMAT-rich BM has HU <115, whereas RM is mostly within 115-
229 300 HU (Fig. 4B); bone was defined as >300 HU. To test the validity of these thresholds we
230 applied them to clinical CT data to determine BMAT volume as % BM volume. We found
231 that BMAT predominated in the arms, legs and sternum but was markedly lower in the
232 clavicle, ribs and vertebrae (Fig. 4C, Fig. S4B). Moreover, %BMAT showed age-associated
233 increases in the axial skeleton but not in long bones (Fig. S4B). These data are consistent
234 with previous studies showing that BMAT predominates in the long bones by early adulthood
235 but continues to accumulate in axial bones beyond 60 years of age (Baum et al., 2018;
236 Kricun, 1985; Schraml et al., 2015). Together, this supports the validity of our CT thresholds
237 for BMAT identification in humans.

238

239

240

Human BMAT is functionally distinct to BAT and is a major site of basal glucose uptake

We then applied these thresholds to human co-registered PET/CT data to assess ^{18}F-FDG uptake in BMAT, RM and bone. To test if BMAT is BAT-like we first compared BMAT ^{18}F-FDG uptake between three groups: subjects with no detectable supraclavicular BAT at room temperature (*No BAT*), subjects with active BAT at room temperature (*Active BAT*), and cold-exposed subjects (16 ºC for 2 h; *Cold*). PET/CT confirmed BAT ^{18}F-FDG uptake in the latter two groups but not in the *No BAT* group (Fig. 4D-E, Fig. S4C). Cold exposure did not alter ^{18}F-FDG uptake in scWAT but was associated with increased uptake in sternal and clavicular bone tissue; however, these were the only skeletal sites at which ^{18}F-FDG uptake significantly differed between the *No BAT, Active BAT* and *Cold* subjects (Fig. 4E, Fig. S4D). Indeed, the *Active BAT* and *Cold* subjects did not have increased glucose uptake in BMAT or RM of any bones analysed (Fig. 4E, Fig. S4D). Thus, consistent with our findings in mice, BMAT glucose uptake in humans is not cold-responsive.

Our previous human PET/CT studies revealed that glucocorticoids acutely activate BAT (Ramage et al., 2016a). Glucocorticoids also promote BMAT accumulation, demonstrating that BMAT can be glucocorticoid-responsive (Scheller et al., 2016). Thus, to further test if BMAT shares properties of BAT, we analysed PET/CT data from previously reported subjects (Ramage et al., 2016a) to determine if glucocorticoids also influence glucose uptake in human BMAT. We found that prednisolone significantly influenced ^{18}F-FDG uptake only in vertebrae, in which there was a trend for increased uptake into RM but not BMAT or bone (Fig. S4E). However, prednisolone did not influence ^{18}F-FDG uptake at any other site. Thus, unlike BAT, BMAT glucose uptake is not glucocorticoid-responsive.

The above findings confirm that, in humans, BMAT is functionally distinct to BAT. However, while analyzing these data, two other phenomena became apparent. Firstly, within axial bones of each subject, BMAT had significantly higher glucose uptake than bone (Fig. 4F). In the sternum, glucose uptake was also greater in BMAT than in RM (Fig. 4F). Secondly, BMAT at each skeletal site had higher glucose uptake than scWAT (Fig. 4G). Thus, despite being unresponsive to insulin or activators of BAT, BMAT has high basal glucose uptake, highlighting its potential to influence systemic glucose homeostasis.

8

DISCUSSION

Unlike WAT and BAT, the role of BMAT in systemic energy metabolism is poorly understood. Previous studies have shed some light on BMAT lipid metabolism *in vivo* (Scheller et al., 2018; Tran et al., 1981), and PET/CT has been used to assess glucose uptake into bones or BM (Huovinen et al., 2016; Huovinen et al., 2014; Nishio et al., 2012; Zoch et al., 2016); however, our study is the first to characterise *in vivo* glucose metabolism specifically in BMAT. Our data provide key insights into how BMAT compares to WAT and BAT; reveal new site-specific differences in BMAT characteristics; and identify BMAT as a major site of skeletal glucose disposal. Moreover, we establish a method for BMAT identification and analysis by PET/CT that will open new avenues for future study of BMAT function.

We show, for the first time, that, compared to WAT, BMAT resists insulin-stimulated glucose uptake. This is supported not only by PET/CT of mouse distal tibial BMAT, but also by the transcriptional profiles of rabbit and human BMAT from other skeletal sites. This conclusion seemingly contrasts with findings elsewhere. For example, adipocyte-specific ablation of *Insr* in mice decreases BMAd size (Qiang et al., 2016), suggesting a role for insulin in BMAd lipogenesis; however, it is unclear if this is through *de novo* lipogenesis from glucose, or via insulin regulating uptake and esterification of fatty acids. In humans, Huovinen *et al* used PET/CT to assess BM ^{18}F-FDG uptake during hyperinsulinaemic euglycemic clamp, concluding that whole BM may be insulin-responsive (Huovinen et al., 2016). Thus, one possibility is that insulin can stimulate BMAT glucose uptake under hyperinsulinaemic conditions. However, unlike our work, Huovinen *et al* did not distinguish BMAT-rich from BMAT-deficient BM, nor did they use a vehicle control to confirm if BM ^{18}F-FDG uptake is genuinely insulin-responsive. Indeed, microarrays show that *SLC2A4* and *IRS1* expression is negligible in human BM (Dezso et al., 2008), while *Slc2a4* and *Irs1* are markedly lower in BM than in WAT or muscle of mice (Thorrez et al., 2008). More recent microarrays show that *Slc2a4, Insr, Irs1* and *Irs2* are lower in BMAds than epididymal white adipocytes of mice (Liu et al., 2011). These data are strikingly consistent with our results for transcript expression in rabbits and humans (Fig. 1, Fig. S1-2) and further support the conclusion that, compared to WAT, BMAT resists insulin-stimulated glucose uptake.

In addition to BMAT, we also found that insulin responsiveness varies among different bones: in insulin-treated mice, bone glucose uptake increases in femurs, decreases in humeri and is unaltered in tibiae. In contrast, Zoch *et al* report that insulin stimulates ^{18}F-FDG uptake into whole femurs and tibiae (Zoch et al., 2016). This discrepancy may relate to technical differences: Zoch *et al* analysed whole bones (including BM) of anesthetised mice, whereas we distinguished between bone and BM and avoided anaesthesia. It is unclear why insulin is associated with decreased glucose uptake in humeral bone and BM; this is unlikely to be a technical issue given that we see expected insulin-stimulated glucose uptake in the heart, WAT and femur. Thus, the lack of increases in humeri and tibiae suggests that there are site-specific differences in skeletal insulin responsiveness.

Another major finding is that BMAT is molecularly and functionally distinct to brown and beige adipose tissues, both for cBMAT of mice and rabbits, and for rBMAT of humans at multiple skeletal sites. These molecular distinctions are consistent with several other studies. We and others previously found that tibial *Ucp1* expression is over 10,000-fold lower than in BAT (Krings et al., 2012; Sulston et al., 2016), consistent with our present finding that *Ucp1* is undetectable in whole mouse bones. Similarly, microarrays show that *UCP1* is not enriched in whole BM of mice or humans (Dezso et al., 2008; Thorrez et al., 2008), nor is it greater in BMAds vs white adipocytes of mice (Liu et al., 2011). Moreover, BMAd progenitors are more white-like than brown-like and do not express brown adipocyte

9

325 markers after adipogenesis *in vitro* (Ambrosi et al., 2017). However, despite these diverse
326 lines of evidence to the contrary, the concept that BMAT may be BAT- or beige-like has
327 persisted. Thus, our *in vivo* functional analyses of mice and humans are a key advance
328 because they confirm that cold exposure does not induce glucose uptake or beiging in
329 BMAT. This demonstrates, conclusively, that BMAT is not BAT- or beige-like.
330
331 Our glucocorticoid studies provide further insights. Unlike in BAT, acute glucocorticoid
332 treatment in humans does not stimulate glucose uptake in BMAT; however, it does influence
333 uptake across lumbar vertebrae, with a trend for increases in RM (Fig. S4E). It is notable
334 that this occurs only in vertebrae, because these are also the bones in which glucocorticoids
335 drive the greatest increases in fracture risk (Briot and Roux, 2015). This raises the possibility
336 that glucocorticoids modulate BM and bone metabolism in a site-specific manner and that
337 these metabolic effects contribute to glucocorticoid-induced osteoporosis. Future studies
338 using different doses and durations of glucocorticoids would further elucidate their ability to
339 modulate metabolism of RM, BMAT and bone, and whether this influences glucocorticoid-
340 induced osteoporosis.
341
342 Although BMAT glucose uptake is not stimulated by insulin at physiological concentrations,
343 cold exposure or glucocorticoids, a major finding is that BMAT in humans has high basal
344 glucose uptake, exceeding that of WAT and greater than that for bone or RM in the axial
345 skeleton. Superficially, this seems at odds with two studies reporting that BM ^{18}F-FDG
346 uptake correlates inversely with BM fat content (Huovinen et al., 2014; Schraml et al., 2015);
347 however, on further consideration, it is clear that these findings are not inconsistent with
348 ours. Indeed, we show that axial bones have less BMAT but greater BM ^{18}F-FDG uptake
349 than humeri or femurs, mirroring these and other previous reports of ^{18}F-FDG uptake in
350 whole BM (Huovinen et al., 2016). Importantly, unlike our approach, no previous studies
351 have distinguished ^{18}F-FDG uptake between RM and BMAT specifically. Thus, a unique
352 advance of our work is the finding that, in axial bones, BMAT glucose uptake is greater than
353 in bone and similar or greater than in RM. This is particularly notable given that both BM and
354 bone are sites of high glucose uptake, capable of exceeding levels observed in WAT or
355 skeletal muscle (Huovinen et al., 2016; Huovinen et al., 2014; Zoch et al., 2016) (Fig. 4, Fig.
356 S4). Indeed, bone glucose uptake is required for normal metabolic function (Li et al., 2016).
357 Together, these observations support the conclusion that BMAT may influence systemic
358 glucose homeostasis.
359
360 We also reveal that BMAT glucose uptake varies at different skeletal sites, generally being
361 greater in axial BMAT compared to BMAT in long bones. This is consistent with depot-
362 dependent differences in other BMAT characteristics and, broadly, with the concept that
363 BMAT exists in regulated and constitutive subtypes (Craft et al., 2018). However, while axial
364 BMAT has higher glucose uptake, BMAT volume in peripheral bones is typically far higher
365 (Fig. 4, Fig. S4) (Kricun, 1985). Thus, the systemic metabolic influence of axial BMAT may
366 be greater in conditions such as ageing, obesity, osteoporosis or caloric restriction, in which
367 axial BMAT accumulates (Scheller et al., 2016).
368
369 Why does BMAT have such high basal glucose uptake? This may result from BMAds having
370 high expression of *SLC2A1* and/or *SLC2A3* (Fig. 1), a finding supported by previous
371 microarray studies (Liu et al., 2011). Indeed, among numerous human tissues, *SLC2A3*
372 expression is highest in BM (Dezso et al., 2008), while *Slc2a3* is also greater in BM than in
373 WAT of mice (Thorrez et al., 2008). Mouse BMAds also have a dense mitochondrial network
374 (Robles et al., 2018) and, by electron microscopy, we found that mitochondria are also
375 abundant in human BMAds (S. Cinti, personal communication). This supports the conclusion

376 that BMAds are metabolically active, which may further explain their high basal glucose
377 uptake.
378
379 Finally, we have developed a method to identify BMAT from CT scans, allowing its functional
380 analysis by PET/CT. At least one other study has used HU thresholding to try to distinguish
381 BMAT-enriched vs BMAT-deficient BM (Rantalainen et al., 2013), but our method is more
382 comprehensive because we directly compared paired MRI and CT scans to identify the
383 optimal BMAT HU thresholds. The finding that the sternum is BMAT-rich was unexpected
384 as this contrasts with most other axial bones; however, it is consistent with adipogenic
385 progenitors being readily detectable within sternal BM (Ambrosi et al., 2017). Otherwise, our
386 method identifies site- and age-dependent differences in RM and BMAT that are in full
387 agreement with previous studies (Baum et al., 2018; Kricun, 1985; Schraml et al., 2015).
388 Applying our PET/CT approach to other clinical and preclinical studies, including
389 retrospectively, therefore holds great promise to reveal further physiological and
390 pathological roles of BMAT. Importantly, the diversity of PET tracers could extend such
391 studies far beyond glucose metabolism, allowing many other functions of BMAT to be
392 addressed.
393
394 In summary, this study is the first to dissect BMAT glucose metabolism *in vivo* and identifies
395 BMAT as a distinct, major subtype of adipose tissue.

11

ACKNOWLEDGEMENTS

12

AUTHOR CONTRIBUTIONS (based on CRediT taxononmy)

Conceptualisation, K.J.S. and W.P.C.; *Methodology*, K.J.S., A.A.S.T, E.L.S., G.P., C.G., L.E.R., W.A.M., A.J.D., A.P., S.C., R.J.W., O.A.M., N.M.M, R.H.S. and W.P.C.; *Investigation*, K.J.S., D.M., E.L.S., L.E.R., G.P., C.G., A.L., R.J.S., B.J.T., M.C.S., B.M.N., C.J.A., D.S., G.J.M., M.R.D., J.P.M.A., M.C.W., R.J.W., E.J.R.v.B., R.H.S. and W.P.C.; *Formal Analysis*, K.J.S., A.A.S.T, D.M., E.L.S., G.P., C.G., W.A.M., J.P.M.A., M.C.W., R.J.W., E.J.R.v.B., N.M.M., R.H.S. and W.P.C.; *Resources*, A.A.S.T, A.P., S.C., G.J.M., M.R.D., J.P.M.A., M.C.W., E.J.R.v.B., N.M.M., R.H.S.; Writing – Original Draft, K.J.S. and W.P.C.; *Writing – Review & Editing*, K.J.S., A.A.S.T, E.L.S., G.P., W.A.M., A.J.D., S.C., M.C.W., R.J.W., E.J.R.v.B., O.A.M., R.H.S, W.P.C.; *Visualisation*, K.J.S. and W.P.C.; Supervision, A.J.D., A.P., M.R.D., O.A.M., N.M.M., R.H.S. and W.P.C.; *Funding Acquisition*, A.J.D., O.A.M., N.M.M., R.H.S. and W.P.C.

13

DECLARATION OF INTERESTS

E.J.R.v.B. has received research support from Siemens Healthineers and is the owner of QCTIS Ltd.

14

435 **FIGURE TITLES AND LEGENDS**
436
437 **Figure 1 – BMAT is transcriptionally distinct to white, brown and beige adipose**
438 **tissues.** (**A-D)** Transcriptional profiling of gonadal WAT, inguinal WAT, and whole BMAT
439 isolated from the proximal tibia (pBMAT), distal tibia (dBMAT) or radius and ulna (ruBMAT)
440 of two cohorts of rabbits. (A) Principal component analysis of both cohorts. (B-D) Volcano
441 plots (B), GSEA (C) and heatmaps (D) of transcripts differentially expressed between BMAT
442 (dBMAT + ruBMAT) and WAT (iWAT + gWAT) in rabbit cohort 1. In (B-E), red text indicates
443 differentially expressed transcripts (B) or transcripts/pathways relating to glucose
444 metabolism and/or insulin responsiveness (C-E); *ns* = not significant. **(E)** Transcriptional
445 profiling of adipocytes isolated from femoral BM or subcutaneous WAT of humans. **(F)**
446 Representative micrographs of H&E-stained sections of human femoral BM, subcutaneous
447 WAT and trabecular bone; scale bar = 150 µm. **(G)** qPCR (G) of adipocytes isolated from
448 tissues in (G). Data are mean ± SEM of the following numbers per group: BM Ads, n = 10;
449 WAT Ads, n = 10; Bone Ads, n = 7 (*except IRS1, where n = 2 only*). For each transcript,
450 significant differences between each cell type are indicated by * (P <0.05), ** (P <0.01) or
451 *** (P <0.001). See also Figure S1 and Figure S2.
452
453 **Figure 2 – Insulin treatment in mice does not induce glucose uptake in BMAT.** Insulin-
454 stimulated glucose uptake was assessed by PET/CT. **(A)** Blood glucose post-insulin or
455 vehicle. **(B,D)** Representative PET/CT images of the torso (B) or legs (D) of vehicle- and
456 insulin-treated mice; some ^{18}F-FDG uptake into skeletal muscle is evident in the image of
457 the vehicle-treated mouse (D), possibly resulting from physical activity. **(C)** Gamma counts
458 of ^{18}F-FDG uptake in iWAT and gWAT, shown as % injected dose per g tissue (%ID/g). **(E)**
459 BMAT analysis by osmium tetroxide staining. BMAT is shown in red in representative µCT
460 reconstructions and quantified as adipose volume relative to total BM volume (Ad.V/Ma.V).
461 **(F)** ^{18}F-FDG uptake in the indicated tissues was determined from PET/CT scans. Data are
462 presented as mean ± SEM of 5-6 mice (A,C,F) or 5-7 mice (E). Significant differences
463 between control and insulin-treated samples are indicated by * (P <0.05), ** (P <0.01) or ***
464 (P <0.001). In (E), groups do not significantly differ if they share the same letter.
465
466 **Figure 3 – Cold exposure does not induce glucose uptake or beiging in BMAT.** Cold-
467 induced glucose uptake was assessed by PET/CT, as described in Figure S3A. **(A)**
468 Representative PET/CT images of control, acute and chronic cold mice show increased ^{18}F-
469 FDG uptake in BAT but not tibiae; some ^{18}F-FDG is evident in skeletal muscle of each group.
470 **(B,C)** ^{18}F-FDG uptake in the indicated tissues was determined by PMOD analysis of PET/CT
471 scans (B) or gamma counting (C). **(D)** Representative micrographs of H&E-stained tissues,
472 showing that cold exposure decreases lipid content in BAT and promotes beiging of iWAT,
473 but these effects do not occur in BMAT; scale bar = 150 µm. **(E-G)** Cold exposure induces
474 brown and beige adipocyte transcripts in BAT and iWAT, but not in whole bones. *ND* = not
475 detectable. Data in (B-C) and (E-G) are shown as mean ± SEM of 7-8 mice per group.
476 Significant differences between groups are indicated by # (P <0.01), * (P <0.05), ** (P <0.01)
477 or *** (P <0.001). See also Figure S3.
478
479 **Figure 4 – Human BMAT is functionally distinct to BAT and is a major site of basal**
480 **glucose uptake.** **(A)** Representative MRI (HASTE) and CT images from one subject. **(B)**
481 HU distribution of scWAT, BMAT-rich BM (sternum) and BMAT-deficient BM (vertebrae).
482 Data are mean ± SEM (n = 33). Thresholds diagnostic for BMAT (<115) and RM (115-300)
483 are indicated by dashed lines. **(C)** CT images of a 32-year-old subject, highlighting BMAT
484 or RM identified using the diagnostic thresholds in (B). Tibiae are shown for completeness
485 but were not present in any other available CT scans. **(D,E)** PET/CT analysis of ^{18}F-FDG
486 uptake in *No BAT, Active BAT* and cold-exposed (*Cold)* subjects. Representative PET/CT

487   scans in (D) highlight the BM cavities of the vertebrae and sternum; arrows indicate ^{18}F-

488   FDG uptake in supraclavicular BAT. **(F,G)** ^{18}F-FDG uptake in bone tissue, RM and BMAT

489   (F), or BMAT and scWAT (G), of room-temperature subjects (*No Bat* and *Active BAT*

490   groups); Fem. = femur, Hum. = humerus, Clav. = clavicle, Vert. = vertebrae, Stern. =

491   sternum. Data are shown as mean $\pm$ SEM (E), paired individual values (F) or box-and-

492   whisker plots (G) of 8 (*No BAT*) or 7 (7 *Active BAT, Cold)* subjects per group. Significant

493   differences between bone, RM and BMAT are indicated by * (P <0.05), ** (P <0.01) or ***

494   (P <0.001). Significant differences between *No BAT, Active BAT* and *Cold* groups are

495   indicated by # (P <0.05) or ### (P <0.001). See also Figure S4.

496 **METHODS**

497 **Table of key resources**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
BIOLOGICAL SAMPLES		
Human bone marrow (*cohort 1*)	Orthopedic and Traumatology Department, Ospedali Riuniti, Ancona, Italy	N/A
Human white adipose tissue (*cohort 1*)	Hepatobiliary and Abdominal Transplantation Surgery, Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, Ancona, Italy	N/A
Human bone marrow and white adipose tissue (*cohort 2*)	Edinburgh Adipose Tissue Biobank	N/A
CHEMICALS		
Collagenase Type I	Worthington Biochemicals	LS004196
18F-Fluorodeoxyglucose	Edinburgh Clinical Research Imaging Centre (Edinburgh, UK)	N/A
Insulin	Eli Lilly (Indianapolis, USA)	Humulin S
Ribozol™	Amresco (USA)	N580
Osmium Tetroxide	Agar Scientific (UK)	AGR1022
OLIGONUCLEOTIDES		
See Table 2	This paper	N/A
EXPERIMENTAL MODELS: Organisms/Strains		
Mouse: C57BL/6J	Charles River	027
Rabbit: New Zealand White	Envigo	HsdIf:NZW
SOFTWARE		
Prism	GraphPad	v8.1.0
Heatmapper	(Babicki et al., 2016)	http://www.heatmapper.ca/
GSEA	(Subramanian et al., 2005).	v3.0 [build: 0160]
NRecon	Bruker microCT (Kontich, Belgium)	v1.6.9.4
CT Analyzer	Bruker microCT (Kontich, Belgium)	v1.13.5.1
PMOD	PMOD Technologies LLC (Zurich, Switzerland)	v3.806
Analyze	AnalyzeDirect (Overland Park, KS, USA)	v12.0
MatLab	Mathworks	R2018b
OTHER		
TSE Phenomaster	TSE	PhenoMaster 1.0 with software version 6.1.9
OneTouch Verio Glucometer	OneTouch	User's manual here

Gamma counter	PerkinElmer (USA)	Wizzard[2]
Preclinical PET/CT scanner	Mediso (Budapest, Hungary)	nanoScan PET/CT 122S
Clinical PET/CT scanner	Siemens Medical Systems (Erlangen, Germany)	Biograph mCT
MRI scanner	Siemens Medical Systems (Erlangen, Germany)	3T Verio
Clinical CT scanner	Toshiba Medical Systems (Japan)	Aquilion ONE

499

Human subjects

500 For human subjects in cohort 1 (Fig. 1E, Supplemental Fig. 2A-B), ethical approval and
501 subject characteristics are as described previously (Mattiucci et al., 2018). For human
502 subjects in cohort 2 (Fig. 1F-G, Supplemental Fig. 2C-D) and those undergoing MRI or
503 PET/CT (Fig. 4, Supplemental Fig. 5-6), all studies were reviewed and approved by the
504 South East Scotland Research Ethics Committee, with informed consent obtained from each
505 subject. Characteristics for cold-exposed, placebo-treated and prednisolone-treated
506 subjects are as described previously (Ramage et al., 2016b). Characteristics for all other
507 subjects are provided below in Table 1.
508

509

Study	Number of Subjects (Male/Female)	Age	BMI	Diabetic	Osteoporotic
BMAd isolation	10 (4/6)	67.1 $\pm$ 5.9	31.6 $\pm$ 6.9	0%	0%
MRI & CT	33 (24/9)	65.7 $\pm$ 8.1	29.1 $\pm$ 4.8	ND	ND
Room temp (no BAT)	10 (2/8)	51.5 $\pm$ 19.6	20.7 $\pm$ 2.4	0%	ND
Room temp (active BAT)	10 (2/8)	51.1 $\pm$ 16.0	21.0 $\pm$ 2.2	0%	ND

510 **Table 1.** Characteristics of subjects in human cohort 2 (*used for BMAd isolation and*
511 *molecular analysis)*, those who underwent paired CT and MRI analysis (*used to identify*
512 *Hounsfield Units for BMAT*), and those without or with detectable BAT at room
513 temperature (*Fig. 4, Supplemental Fig. 5-6).* Age and BMI are mean $\pm$ SD. *ND* = not
514 determined.

515

Animals

516
517 Studies in New Zealand White rabbits were approved by the University of Michigan
518 Committee on the Use and Care of Animals, with daily care overseen by the Unit for
519 Laboratory Animal Medicine. Rabbit housing, monitoring and tissue isolation were done as
520 described previously (Cawthorn et al., 2016). For cohort 1 (Fig. 1), male rabbits (3.14 ± 0.19
521 kg, mean ± SD) were fed a high-fiber diet (cat. No 5326, LabDiet), receiving 100 g/day (31.91
522 ±0.19 g/kg body mass/day; mean ±SD) until 22 weeks of age. For cohort 2 (Supplemental
523 Fig. 1), male rabbits were fed the same high-fiber diet *ad libitum* (68.26 ± 4.82 g/kg body
524 mass/day; mean ±SD) until 13 weeks of age. Rabbits in each cohort were then euthanized
525 and tissues isolated for subsequent analysis.

526

527 Studies in C57BL/6JCrl mice were approved by the University of Edinburgh Animal Welfare
528 and Ethical Review Board and were done under project licenses granted by the UK Home

528 Office. Male C57BL/6J mice were bred in-house and housed on a 12 h light/dark cycle with
529 free access to water and food, as indicated.
530

Human cell and tissue isolation

532 For cohort 1, adipocytes were isolated from femoral head bone marrow (BMAds) or
533 subcutaneous WAT (WAT Ads) as described previously (Mattiucci et al., 2018). For cohort
534 2, adipocytes from bone marrow, trabecular bone and WAT were isolated from patients
535 undergoing hip-replacement surgery: BMAds were obtained from the proximal femoral
536 diaphysis; trabecular bone adipocytes were from the proximal femoral metaphysis; and WAT
537 Ads were from gluteofemoral subcutaneous WAT. Immediately after surgical isolation,
538 tissues were washed and stored in ice-cold Dulbecco's phosphate-buffered saline (DPBS,
539 14190250, Gibco) for transport to a sterile tissue culture hood. Therein, DPBS was decanted
540 through a sterile 300 μm nylon filter to remove blood, lipid and small debris. The remaining
541 washed tissue was then transferred to a sterile, pre-weighed petri dish (100 mm) and tissue
542 mass recorded. A solution of collagenase type I (Worthington Biochemicals) was made at 1
543 mg/mL in Krebs-Ringer HEPES (KRH) buffer (120 mM NaCl, 2 mM KCl, 1 mM KH_2PO_4, 0.6
544 mM $MgSO_4$, 1 mM $CaCl_2$*$2H_2O$, 82 mM HEPES, 5.5 mM D-Glucose, 1% BSA) pre-warmed
545 to 37ºC; sufficient volume was made to allow for 2 mL per mg tissue and the solution was
546 passed through a 0.22 μm filter before use.
547

548 After weighing, each tissue was minced in the petri dish using a sterile scalpel and scissors,
549 then transferred to a Falcon tube containing the collagenase solution. Tissues in
550 collagenase were then incubated for 45 min in a shaking water bath (120 rpm) at 37ºC. Next,
551 collagenase-digested tissue was passed through a 300 μm nylon filter and the cells within
552 the filtrate were washed with fresh KRH buffer. Samples were then centrifuged at 500 rcf for
553 5 min at 4ºC. The floating adipocyte layer was transferred by pipette to a new tube to be
554 used for RNA isolation; an aliquot was also analyzed histologically to confirm the presence
555 of adipocytes. After aspirating and discarding the supernatant, the stromal vascular fraction
556 (SVF) of cells within the pellet was resuspended in 2x volume of red blood cell lysis buffer
557 (Cat. No. R7757, Sigma) and incubated at room temperature for 5 min to lyse erythrocytes.
558 KRH buffer was added to bring the volume to 15 mL and samples were centrifuged at 700
559 rcf for 10 min at 4ºC. The SVF pellet was then used for RNA isolation.
560

RNA isolation and reverse transcription

562 For human cohort 1, RNA was extracted as described previously (Mattiucci et al., 2018). For
563 human cohort 2 and mouse studies, RNA was isolated from cells or tissues using Ribozol™
564 solution (cat. No. N580, Amresco, USA,) according to the manufacturer's protocol. For rabbit
565 studies, RNA was isolated from tissues as described previously (Cawthorn et al., 2016).
566 Tissues included iWAT, gWAT, dBMAT and ruBMAT of both cohorts, and pBMAT of rabbit
567 cohort 2. RNA was quantified using a NanoDrop spectrophotometer (Thermo Scientific,
568 USA), and cDNA was synthesized using the Taqman® High Capacity cDNA Reverse
569 Transcriptase Kit (Applied Biosystems, USA, cat. no. N8080234), in accordance with the
570 manufacturer's guidelines.
571

Microarray analyses

573 For human cohort 1, RNA extraction, generation of single-strand biotinylated cDNA, and
574 hybridization to Human GeneChip® HTA 2.0 Arrays (Affymetrix) were done as described
575 previously (Mattiucci et al., 2018). Transcripts were considered to be significantly
576 differentially expressed between BMAds and WAT Ads when they had an adjusted *p*-value
577 of 0.05 or less; *p*-values were adjusted for multiple comparisons using the Benjamini and
578 Hochberg approach to control for false discovery rate (Benjamini and Hochberg, 1995).

579
580 For rabbit studies, purified RNA was digested on-column with DNase I and cleaned using
581 the Qiagen RNeasy kit (Qiagen, Valencia, CA, USA) as recommended by the manufacturer.
582 Total RNA was then submitted to the microarray core at the University of Michigan. The
583 samples were screened for quality and processed in the microarray facility using custom
584 rabbit Affymetrix arrays and the IVT Express kit (Affymetrix, Santa Clara, CA, USA). As a
585 QC measure, the distribution of probe intensities and the 5' to 3' degradation profiles were
586 checked to be consistent across samples. The core's statistician used RMA, from the Affy
587 package of Bioconductor, to fit $\log_2$ expression values to the data (Irizarry et al., 2003).
588 Weighted, paired, linear models were then fit and contrast computed using the limma
589 package (Smyth, 2004). Weighting was done using a gene-by-gene algorithm designed to
590 down-weight chips that were deemed less reproducible (Ritchie et al., 2006). Probe-sets
591 with a variance over all samples less than 0.05 were filtered out. Of the remainder, probe-
592 sets with a $\log_2$-fold change of 2 or greater and an adjusted p-value of 0.05 or less were
593 retained. P-values were adjusted for multiple comparisons using the Benjamini and
594 Hochberg false discovery rate approach (Benjamini and Hochberg, 1995). Affy, affyPLM,
595 and limma packages of Bioconductor, implemented in the R-statistical environment were
596 used to analyze the data, including PCA analysis (Irizarry et al., 2003).
597
598 Pathways enriched in BMAT (combined dBMAT and ruBMAT) or WAT (combined iWAT and
599 gWAT) of rabbits, or in isolated adipocytes from femoral BM and gluteofemoral scWAT
600 (humans), were identified using Gene Set Enrichment Analysis (GSEA) software and the
601 Molecular Signature Database (MSigDB) (Subramanian et al., 2005). For rabbits, pBMAT
602 was not included in these analyses because it contained a high proportion of red marrow
603 and therefore represented a less pure BMAT sample (Cawthorn et al., 2016). To ensure
604 maximum compatibility with this software, rabbit gene identifiers were first converted to their
605 corresponding human homologues using the BetterBunny algorithm (Craig et al., 2012).
606 Volcano plots and heat maps (*Pearson Distance)* to visualize significantly differentially
607 expressed transcripts (adjusted *p*-value <0.05, fold-change >2) were generated using Prism
608 8 (GraphPad) and Heatmapper software (Babicki et al., 2016), respectively.
609

610 **qPCR**
611 For human cohort 2 and tissues from mice, reverse transcription, primer design/validation
612 and qPCR were done as described previously (Sulston et al., 2016). Expression of each
613 target gene was normalized to expression of 18S rRNA (human gene, *RNA18SN5;* mouse
614 gene, *Rn18s*), *IPO8* or *Ppia,* based on consistency of housekeeper expression across all
615 samples. For each transcript, expression is presented relative to the group with the highest
616 expression. A Taqman assay was used to analyze *Ucp1* expression in mouse tissues
617 (Thermo Fisher, Mm01244861_m1). All other primer sequences are described in Table 2.
618

619 **Histology**
620 Fixed murine and human soft tissue and decalcified bones (14% EDTA for 14 days) were
621 paraffin embedded by the histology core at The University of Edinburgh's Shared University
622 Research Facilities (SuRF). Paraffin-embedded tissue sections were then sectioned at 100
623 μm intervals using a Leica RM2125 RTS microtome and collected onto 76 x 26 mm StarFrost
624 slides (VWR, UK). The slides were baked at 37ºC overnight before Hemotoxylin and Eosin
625 (H&E) staining.
626
627
628
629

Species	Transcript	Forward Primer (5'-3')	Reverse Primer (5'-3')
H. Sapiens	ADIPOQ	TCCTCACTTCCATTCTGACTGC	GTAGAACAGCTCCCAGCAACA
	CPT1B	CTGGTGCTCAAGTCATGGTG	CTGCCTGCACGTCTGTATTC
	INSR	TAGACGTCCCGTCAAATATTGC	GAAGAAGCGTAAAGCGGTCC
	IPO8	TTTCCCCTCAAATGTGGCAGC	CTTCTCCTGCATCTCCACATAGT
	IRS1	AGAGGACCGTCAGTAGCTCA	TCTCTCATGACACGGTGGTG
	IRS2	CACCTACGCCAGCATTGACT	GAAACAGTGCTGAGCGTCTTC
	METRNL	CCACAGGCTTCCAGTACGAG	TCAGGCTCGTGGGTAACTTG
	PPARG	TCATGCTTGTGAAGGATGCAAG	ATCCCCACTGCAAGGCATTT
	PRDM16	GAGGAGAGAGATTCCGCGAG	CCCGGTTGGGCTCATACAT
	RNA18SN5	CGATGCTCTTAGCTGAGTGT	GGTCCAAGAATTTCACCTCT
	SLC2A1	TCCCTGCAGTTTGGCTACAA	CAGGATGCTCTCCCCATAGC
	SLC2A3	TAGATTACAGCGATGGGGACAC	GTAGCCAAATTGGAAAGAGCCG
	SLC2A4	TCGGGCTTCCAACAGATAGG	GTTGTACCCAAACTGCAGGG
	TGM2	GGAGTATGTCCTCACCCAGC	CGTTCTTCAGGAACTTGGGGT
	UCP1	GTGTGCCCAACTGTGCAATG	ACGTTCCAGGATCCAAGTCG
M. musculus	Cpt1b	TGTCTACCTCCGAAGCAGGA	CGGCTTGATCTCTTCACGGT
	Dio2	TCTTCCTGGCGCTCTATGAC	ACCACACTGGAATTGGGAGC
	Ppara	CCTGAACATCGAGTGTCGAATAT	TCTTCTTCTGAATCTTGCAGCT
	Pparg	GGAAAGACAACGGACAAATCAC	TACGGATCGAAACTGGCAC
	Ppia	CACCGTGTTCTTCGACATCA	CAGTGCTCAGAGCTCGAAAGT
	Prkaa1	ACCAGGTCATCAGTACACCATC	ACACCGGAAAGGATCTGCTG
	Rn18s	CGATGCTCTTAGCTGAGTGT	GGTCCAAGAATTTCACCTCT
	Slc2a4	ACTCATTCTTGGACGGTTCCTC	CACCCCGAAGATGAGTGGG

Table 2. Sequences of primers used for qPCR.

Mouse insulin-treatment studies

C57BL/6J male mice aged ~16 weeks were fasted for 4 h at room temperature (RT). Insulin (Humulin S, Eli Lilly; 0.75 mIU/g body mass) or sterile saline (0.9%) was then adminstred to to mice via intraperitoneal injection immediately prior to ^{18}F-FDG injection. Mice were then returned to their cages. At 0 min (just before ^{18}F-FDG injection), 15- and 60-min post-^{18}F-FDG blood glucose was measured by tail venesection and blood sampled directly into EDTA-microtubes (Sarstedt, Leicester, UK). Mice were then anesthetised and ^{18}F -FDG distribution assessed by PET/CT. After PET/CT, mice were sacrificed by overdose of anesthetic. BAT, iWAT, gWAT, pWAT, mWAT, gonads, brain, kidneys, liver, spleen, pancreata, heart, soleus, gastrocnemius, femur, tibiae, humeri, and tail vertebrae were then dissected and ^{18}F -FDG uptake into each tissue was determined using a gamma counter (PerkinElmer). Counts per minute were converted to MBq activity using a standard conversion factor calibrated for the gamma counter. MBq were then corrected for radioactive decay based on the time of ^{18}F -FDG administration and the time of gamma counting. Finally, the corrected MBq values were normalized to the mass of each tissue. The final gamma counts are therefore presented as % injected dose per g tissue (%ID/g). Frozen and fixed

648 tissues were analyzed separately and the average MBq for each tissue was then calculated.
649 Half of the dissected material was then snap frozen on dry ice and stored at -80ºC for
650 molecular analyses. The remaining half of the dissected material was placed into 10%
651 formalin and stored at 4ºC for histological analysis. PET/CT analysis was then done as
652 described below.
653
654 **Mouse cold-exposure studies**
655 The protocol is adapted from (Wang et al., 2012), with a summary depicted in Supplemental
656 Figure 3A. For the acute and chronic cold exposure studies (Fig. 3, Supplemental Fig. 4B-
657 H), male C57BL/6J mice aged ~18 weeks were housed individually in TSE PhenoMaster
658 cages for indirect calorimetry, monitoring of physical activity, and measurement of *ad libitum*
659 food and water consumption. Mice in each group were first housed in these cages for 3 days
660 at room temperature (RT) for acclimation and baseline measurements. Group 1 *(Control)*
661 were then housed for 72 h at RT in standard cages; group 2 *(Acute cold)* for 68 h at RT in
662 standard cages, followed by 4 h at 4ºC in TSE cages; and group 3 (*Chronic cold)* for 72 h at
663 4ºC in TSE cages. Following TSE housing at 4ºC, *Acute cold* and *Chronic cold* mice were
664 returned to standard cages that had been pre-cooled on ice to 4 ºC; *Control* mice continued
665 to be housed in standard cages at RT. All groups were fasted, with access to water, for 4 h
666 before administration of ^{18}F -FDG (such that *Acute cold* mice were fasted throughout their 4
667 h cold exposure). Cages of cold-exposed mice were stored on ice in a ventilated cooler for
668 transport to the PET/CT facility, while *Control* mice were transported at RT. After
669 intraperitoneal injection of ^{18}F -FDG, mice were returned to cages at RT (*Control*) or 4ºC
670 (*Acute* and *Chronic cold*). At 0 min (just before ^{18}F -FDG injection), 15- and 60-min post-^{18}F
671 -FDG, blood glucose was measured by tail venesection. At 60-min post-^{18}F -FDG, mice were
672 placed under general anesthesia and underwent PET/CT imaging. Euthanasia, tissue
673 isolation and gamma counting were done as described above for the insulin-treatment
674 studies. PET/CT analysis was then done as described below.
675
676 To assess effects of cold exposure compared to mice housed at thermoneutrality, male
677 C57BL/6J mice aged 12 weeks were individually housed for 48 h at 28ºC, 22ºC or 4ºC. Each
678 group was given AL access to chow diet throughout. Mice were then euthanised for tissue
679 isolation.
680
681 **Mouse PET/CT analysis**
682 PET/CT scan images were reconstructed and data was analyzed using PMOD version 3.806
683 (PMOD, Zurich, Switzerland). Standardised uptake values (SUV) were calculated for regions
684 of interest, namely BAT, iWAT, gWAT; heart; bone tissue (without BM) from tibiae, femurs,
685 and humeri; and the BM cavities within these bones. To distinguish bone tissue from BM, a
686 calibration curve was generated using HU obtained from the acquisition of a CT tissue
687 equivalent material (TEM) phantom (CIRS, model 091) and mouse CT scans. The TEM
688 phantom consists of 2-4 mm hydroxyapatite rods representing mass densities of 1.08 to
689 1.57 g/mL. The TEM-reconstructed CT image data was exported for analysis into PMOD
690 and, for the extraction of TEM HU values, a VOI template was generated and placed on
691 each rod (0.008mL for 2mm and 0.05mL 4mm). The calibration curve was plotted based on
692 the calculated linear equation of the TEM HU values, in which the mouse tissue values were
693 inserted/scaled. This ensured that, within whole bones, regions of interest were specific for
694 bone or BM.
695
696 **Human PET/CT studies**
697 Subjects with active BAT at room temperature were identified retrospectively from clinical
698 PET/CT scans; a control group, without detectable BAT, was then identified, ensuring that
699 age, sex, weight, BMI and fasting blood glucose were matched to the active-BAT group. To

22

assess effects of cold exposure, subjects were exposed to a mild cold (16 ºC) for 2 h, as described previously *(Ramage et al., 2016b).* To assess effects of prednisolone treatment, subjects were recruited to a double-blind, randomized crossover study, as described previously *(Ramage et al., 2016b)*. All subjects were placed supine in a hybrid PET/CT scanner (Biograph mCT, Siemens Medical Systems) and scanned as described previously (Ramage et al., 2016b).

Determination of attenuation density for BMAT in humans

HU of subcutaneous fat, yellow marrow and red marrow were determined using Analyze 12.0 software (AnalyzeDirect, Overland Park, KS, USA) based on data from 33 patients who had undergone paired CT and MRI scans (Table 1). The MRI sequence was an axial HASTE (Half Acquisition Single Shot Turbo Spin Echo) with a TE (echo time) of 50 ms, TR (repetition time) of 1000 ms, and slice thickness 8mm. BM fat corresponds to higher signal intensity compared to surrounding bone and muscle tissues, in HASTE MR techniques. CT scanning was performed as described previously (Williams et al., 2017). Using Analyze 12.0 software, the MR and CT scans were co-registered and volumes of interest were manually drawn around the sternum, vertebrae and subcutaneous adipose tissue. HU were extracted on a per voxel basis, and data underwent post-processing using Matlab to measure the total number of voxels across all patient HU (Fig. 4B), prior to ROC analysis (MedCalc). ROC analysis was then conducted on per voxel HU to determine threshold values with the greatest sensitivity and specificity to detect bone, yellow marrow and red marrow. Thresholds of above 300 HU were defined as bone regions, -200 to 115 HU as yellow marrow and 115 to 300 as red marrow.

Micro-computed tomography scanning (μCT)

Following euthanasia, murine tibiae were isolated, thoroughly cleaned and fixed in 10% formalin at 4°C for 48 hours. Bones were decalcified for 14 days in 14% EDTA and washed in Sorensen's phosphate buffer. Bones were then stained for 48 hours in 1% osmium tetroxide (Agar Scientific, UK), washed in Sorensen's phosphate buffer and embedded in 1% agarose, forming layers of five tibiae arranged in parallel in a 30-mL universal tube. Tubes of embedded tibiae were then mounted in a Skyscan 1172 desktop micro CT (Bruker microCT, Kontich, Belgium). Samples were scanned through 360° using a step of 0.40° between exposures. A voxel resolution of 12.05 μm was obtained in the scans using the following control settings: 54 kV source voltage, 185 μA source current with an exposure time of 885 ms. A 0.5 mm aluminum filter and two-frame averaging were used to optimize the scan. After scanning, the data were reconstructed using NRecon v1.6.9.4 software (Bruker, Kontich, Belgium). The reconstruction thresholding window was optimized to encapsulate the target image. Volumetric analysis was performed using CT Analyzer v1.13.5.1 (Bruker microCT, Kontich, Belgium).

Statistical analysis

Microarray data were analyzed as described above. All other data were analyzed for normal distribution using the Shapiro-Wilk normality test. Normally distributed data were analyzed by ANOVA or t-tests, as appropriate. Where data were not normally distributed, non-parametric analyses were used. When appropriate, *P* values were adjusted for multiple comparisons. Data are presented as histograms or box and whisker plots. For the latter, boxes indicate the 25th and 75th percentiles; whiskers display the range; and horizontal lines in each box represent the median. All statistical analyses were performed using Prism software (GraphPad, USA). A *P*-value <0.05 was considered statistically significant.

SUPPLEMENTAL FIGURE LEGENDS

Figure S1, Related to Figure 1 – BMAT is transcriptionally distinct to white, brown and beige adipose tissues. Transcriptional profiling of WAT (gonadal + inguinal) vs whole BMAT (dBMAT + ruBMAT) from rabbit cohort 2. **(A)** Volcano plot of differentially expressed transcripts (FDR < 0.05, fold-change > 2). Transcripts characteristic of brown and/or beige adipocytes are labelled. Those with significant differential expression between WAT and BMAT are shown in red; those not differentially expressed are in grey. **(B)** Gene set enrichment analysis (GSEA) highlights lipid metabolism, glucose metabolism and insulin responsiveness as key pathways differentially regulated between WAT and BMAT.

Figure S2, Related to Figure 1 – BM adipocytes in humans are transcriptionally distinct to those from WAT. Transcriptional profiling (A,B) and qPCR analysis (C,D) of adipocytes isolated from the subcutaneous WAT or femoral diaphyseal BM of humans undergoing hip-replacement surgery. **(A,B)** Volcano plots (A) and heat maps (B) are presented as for Figures 1 and S1. **(C,D)** qPCR to validate purity of adipocytes isolated from each tissue (C) and showing that BM adipocytes generally do not have increased expression of brown or beige adipocyte markers (D). Transcript expression was normalised to expression of *IPO8* (C) or *RNA18SN5* (D). Data in (C) are mean ± SEM of the following numbers per group: BM Ads, n = 8 (*ADIPOQ)* or 9 *(PPARG)*; BM SVF, n = 3 (*ADIPOQ)* or 5 *(PPARG)*; WAT Ads, n = 10 *(ADIPOQ* and *PPARG)*; WAT SVF, n = 5 *(ADIPOQ* and *PPARG)*; Bone Ads and SVF, n = 7 *(PPARG)* or 3 *(ADIPOQ)*. Data in (D) are mean ± SEM of the following numbers per group: BM Ads, n = 3-10; WAT Ads, n = 6-10; Bone Ads, n = 3-7. For each transcript, significant differences are indicated as for Figure 1.

Figure S3, Related to Figure 3 – Effects of cold exposure on energy homeostasis and gene expression in BAT, iWAT and bone. (A) Protocol for cold exposure and calorimetry studies, as described in the STAR Methods. **(B-H)** Effects of cold exposure on energy expenditure (B), body mass (C), baseline blood glucose (D), 72 h food intake (E) and transcript expression in BAT, iWAT or whole femurs (F-H). In (E), *Acute cold* mice are not shown because they were fasted throughout cold exposure. **(I)** A separate cohort of mice was housed at thermoneutrality, 22 ºC or 4 ºC for 48 h. Expression of BAT or beige cold exposure markers was then determined by qPCR of whole femurs. *ND* = not detectable. In (F-I), transcript expression was normalised to expression of *Rn18s* (F,H,I) or *Ppia* (G); the latter was used for iWAT because in this tissue *Rn18s,* but not *Ppia,* showed significant regulation between the three groups. Data are shown as box-and-whisker plots (B-E) or as mean ± SEM (F-H) of 7-8 mice per group. In (I), data are mean ± SEM of 8-10 mice per group. Significant differences between groups are indicated by * (*P* <0.05), ** (*P* <0.01) or *** (*P* <0.001).

Figure S4, Related to Figure 4 – PET/CT for identification and functional analysis of BMAT in humans. (A) ROC analysis to identify HU thresholds to distinguish BMAT-rich (sternum) from BMAT-deficient (vertebrae) regions of BM. **(B)** Quantification of BMAT in CT scans of male and female subjects aged <60 or >60 years. A HU threshold of <115 was used to identify BMAT voxels in BM of the indicated bones, and total BM volume was also determined. The proportion of the BM cavity corresponding to BMAT (Ad.V/Ma.V) was then calculated. Data are shown as box-and-whisker plots of the following numbers of subjects for each group: <60 years, n = 28 (humerus), 9 (femur), or 27 (clavicle, sternum and vertebrae); >60 years, n = 7 for each bone. Significant differences between <60 and >60 groups are indicated by ** (*P* <0.01). **(C)** Representative coronal PET/CT images of *No BAT, Active BAT* and *Cold* subjects. ^{18}F-FDG uptake in BAT is evident in the *Active BAT* and *Cold* subjects (arrows). Femurs were not included in scans of the *Cold* group. **(D)** ^{18}F-FDG uptake

801   in bone tissue, RM and BMAT of the indicated bones. Data are shown as mean $\pm$ SEM of 8

802   (*No BAT*) or 7 (7 *Active BAT, Cold)* subjects per group. Significant differences between

803   these groups *No BAT, Active BAT* and *Cold* groups are indicated by # (P <0.05). **(E)**

804   Subjects were treated with prednisolone or placebo control prior to analysis of ^{18}F-FDG

805   uptake by PET/CT. Data are shown as paired individual values for each subject. For each

806   skeletal site, the influence of treatment or tissue (bone, RM, BMAT), and interactions

807   between these, were determined by 2-way ANOVA; P values are shown beneath the graph.

REFERENCES

Abel, E.D., Peroni, O., Kim, J.K., Kim, Y.B., Boss, O., Hadro, E., Minnemann, T., Shulman, G.I., and Kahn, B.B. (2001). Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature *409*, 729-733.

Ambrosi, T.H., Scialdone, A., Graja, A., Gohlke, S., Jank, A.M., Bocian, C., Woelk, L., Fan, H., Logan, D.W., Schurmann, A., et al. (2017). Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration. Cell Stem Cell *20*, 771-784 e776.

Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J.R., Maciejewski, A., and Wishart, D.S. (2016). Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res *44*, W147-153.

Baum, T., Rohrmeier, A., Syväri, J., Diefenbach, M.N., Franz, D., Dieckmeyer, M., Scharr, A., Hauner, H., Ruschke, S., Kirschke, J.S., et al. (2018). Anatomical Variation of Age-Related Changes in Vertebral Bone Marrow Composition Using Chemical Shift Encoding-Based Water–Fat Magnetic Resonance Imaging. Front Endocrinol *9*, 141.

Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological) *57*, 289-300.

Briot, K., and Roux, C. (2015). Glucocorticoid-induced osteoporosis. RMD Open *1*, e000014.

Carvalho, E., Kotani, K., Peroni, O.D., and Kahn, B.B. (2005). Adipose-specific overexpression of GLUT4 reverses insulin resistance and diabetes in mice lacking GLUT4 selectively in muscle. Am. J. Physiol. Endocrinol. Metab. *289*, E551-561.

Cawthorn, W.P., Scheller, E.L., Learman, B.S., Parlee, S.D., Simon, B.R., Mori, H., Ning, X., Bree, A.J., Schell, B., Broome, D.T., et al. (2014). Bone Marrow Adipose Tissue Is an Endocrine Organ that Contributes to Increased Circulating Adiponectin during Caloric Restriction. Cell Metab. *20*, 368-375.

Cawthorn, W.P., Scheller, E.L., Parlee, S.D., Pham, H.A., Learman, B.S., Redshaw, C.M., Sulston, R.J., Burr, A.A., Das, A.K., Simon, B.R., et al. (2016). Expansion of Bone Marrow Adipose Tissue During Caloric Restriction Is Associated With Increased Circulating Glucocorticoids and Not With Hypoleptinemia. Endocrinology *157*, 508-521.

Chapman, J., and Vega, F. (2017). Incidental brown adipose tissue in bone marrow biopsy. Blood *130*, 952.

Cinti, S. (2018). Adipose Organ Development and Remodeling. Compr Physiol *8*, 1357-1431.

Craft, C.S., Li, Z., MacDougald, O.A., and Scheller, E.L. (2018). Molecular differences between subtypes of bone marrow adipocytes. Curr Mol Biol Rep *4*, 16-23.

Craig, D.B., Kannan, S., and Dombkowski, A.A. (2012). Augmented annotation and orthologue analysis for Oryctolagus cuniculus: Better Bunny. BMC Bioinformatics *13*, 84.

Dezso, Z., Nikolsky, Y., Sviridov, E., Shi, W., Serebriyskaya, T., Dosymbekov, D., Bugrim, A., Rakhmatulin, E., Brennan, R.J., Guryanov, A., et al. (2008). A comprehensive functional analysis of tissue specificity of human gene expression. BMC biology *6*, 49.

Huovinen, V., Bucci, M., Lipponen, H., Kiviranta, R., Sandboge, S., Raiko, J., Koskinen, S., Koskensalo, K., Eriksson, J.G., Parkkola, R., et al. (2016). Femoral Bone Marrow Insulin Sensitivity Is Increased by Resistance Training in Elderly Female Offspring of Overweight and Obese Mothers. PLoS One *11*, e0163723.

Huovinen, V., Saunavaara, V., Kiviranta, R., Tarkia, M., Honka, H., Stark, C., Laine, J., Linderborg, K., Tuomikoski, P., Badeau, R.M., et al. (2014). Vertebral bone marrow glucose uptake is inversely associated with bone marrow fat in diabetic and healthy pigs: [(18)F]FDG-PET and MRI study. Bone *61*, 33-38.

855 Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U., and Speed,
856   T.P. (2003). Exploration, normalization, and summaries of high density oligonucleotide array
857   probe level data. Biostatistics *4*, 249-264.

858 Kricun, M.E. (1985). Red-yellow marrow conversion: its effect on the location of some solitary bone
859   lesions. Skeletal Radiol. *14*, 10-19.

860 Krings, A., Rahman, S., Huang, S., Lu, Y., Czernik, P.J., and Lecka-Czernik, B. (2012). Bone
861   marrow fat has brown adipose tissue characteristics, which are attenuated with aging and
862   diabetes. Bone *50*, 546-552.

863 Li, Z., Frey, J.L., Wong, G.W., Faugere, M.C., Wolfgang, M.J., Kim, J.K., Riddle, R.C., and
864   Clemens, T.L. (2016). Glucose Transporter-4 Facilitates Insulin-Stimulated Glucose Uptake in
865   Osteoblasts. Endocrinology *157*, 4094-4103.

866 Liu, L.F., Shen, W.J., Ueno, M., Patel, S., and Kraemer, F.B. (2011). Characterization of age-
867   related gene expression profiling in bone marrow and epididymal adipocytes. BMC Genomics
868   *12*, 212.

869 Mattiucci, D., Maurizi, G., Izzi, V., Cenci, L., Ciarlantini, M., Mancini, S., Mensa, E., Pascarella, R.,
870   Vivarelli, M., Olivieri, A., et al. (2018). Bone marrow adipocytes support hematopoietic stem cell
871   survival. J. Cell. Physiol. *233*, 1500-1511.

872 Nishio, M., Yoneshiro, T., Nakahara, M., Suzuki, S., Saeki, K., Hasegawa, M., Kawai, Y., Akutsu,
873   H., Umezawa, A., Yasuda, K., et al. (2012). Production of functional classical brown adipocytes
874   from human pluripotent stem cells using specific hemopoietin cocktail without gene transfer.
875   Cell Metab. *16*, 394-406.

876 Qiang, G., Whang Kong, H., Xu, S., Pham, H.A., Parlee, S.D., Burr, A.A., Gil, V., Pang, J., Hughes,
877   A., Gu, X., et al. (2016). Lipodystrophy and severe metabolic dysfunction in mice with adipose
878   tissue-specific insulin receptor ablation. Mol Metabol *5*, 480-490.

879 Ramage, L.E., Akyol, M., Fletcher, A.M., Forsythe, J., Nixon, M., Carter, R.N., van Beek, E.J.,
880   Morton, N.M., Walker, B.R., and Stimson, R.H. (2016a). Glucocorticoids Acutely Increase Brown
881   Adipose Tissue Activity in Humans, Revealing Species-Specific Differences in UCP-1
882   Regulation. Cell Metab. *24*, 130-141.

883 Ramage, Lynne E., Akyol, M., Fletcher, Alison M., Forsythe, J., Nixon, M., Carter, Roderick N.,
884   van Beek, Edwin J., Morton, Nicholas M., Walker, Brian R., and Stimson, Roland H. (2016b).
885   Glucocorticoids Acutely Increase Brown Adipose Tissue Activity in Humans, Revealing Species-
886   Specific Differences in UCP-1 Regulation. Cell Metabolism *24*, 130-141.

887 Rantalainen, T., Nikander, R., Heinonen, A., Cervinka, T., Sievanen, H., and Daly, R.M. (2013).
888   Differential effects of exercise on tibial shaft marrow density in young female athletes. J. Clin.
889   Endocrinol. Metab. *98*, 2037-2044.

890 Ritchie, M.E., Diyagama, D., Neilson, J., van Laar, R., Dobrovic, A., Holloway, A., and Smyth, G.K.
891   (2006). Empirical array quality weights in the analysis of microarray data. BMC Bioinformatics *7*,
892   261.

893 Robles, H., Park, S., Joens, M.S., Fitzpatrick, J.A.J., Craft, C.S., and Scheller, E.L. (2018).
894   Characterization of the bone marrow adipocyte niche with three-dimensional electron
895   microscopy. Bone *118*, 89-98.

896 Rosell, M., Kaforou, M., Frontini, A., Okolo, A., Chan, Y.W., Nikolopoulou, E., Millership, S.,
897   Fenech, M.E., MacIntyre, D., Turner, J.O., et al. (2014). Brown and white adipose tissues:
898   intrinsic differences in gene expression and response to cold exposure in mice. Am. J. Physiol.
899   Endocrinol. Metab. *306*, E945-964.

900 Sakaguchi, M., Fujisaka, S., Cai, W., Winnay, J.N., Konishi, M., O'Neill, B.T., Li, M., Garcia-Martin,
901   R., Takahashi, H., Hu, J., et al. (2017). Adipocyte Dynamics and Reversible Metabolic
902   Syndrome in Mice with an Inducible Adipocyte-Specific Deletion of the Insulin Receptor. Cell
903   Metab. *25*, 448-462.

904 Scheller, E.L., Cawthorn, W.P., Burr, A.A., Horowitz, M.C., and MacDougald, O.A. (2016). Marrow
905   Adipose Tissue: Trimming the Fat. Trends Endocrinol Metab 27, 392-403.

906 Scheller, E.L., Khandaker, S., Learman, B.S., Cawthorn, W.P., Anderson, L.M., Pham, H.A.,
907   Robles, H., Wang, Z., Li, Z., Parlee, S.D., et al. (2018). Bone marrow adipocytes resist lipolysis
908   and remodeling in response to beta-adrenergic stimulation. Bone 118, 32-41.

909 Schraml, C., Schmid, M., Gatidis, S., Schmidt, H., la Fougere, C., Nikolaou, K., and Schwenzer,
910   N.F. (2015). Multiparametric analysis of bone marrow in cancer patients using simultaneous
911   PET/MR imaging: Correlation of fat fraction, diffusivity, metabolic activity, and anthropometric
912   data. J. Magn. Reson. Imaging 42, 1048-1056.

913 Smyth, G.K. (2004). Linear models and empirical bayes methods for assessing differential
914   expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article3.

915 Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich,
916   A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: a
917   knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad.
918   Sci. U. S. A. 102, 15545-15550.

919 Sulston, R.J., and Cawthorn, W.P. (2016). Bone marrow adipose tissue as an endocrine organ:
920   close to the bone? Horm Mol Biol Clin Investig 28, 21-38.

921 Sulston, R.J., Learman, B.S., Zhang, B., Scheller, E.L., Parlee, S.D., Simon, B.R., Mori, H., Bree,
922   A.J., Wallace, R.J., Krishnan, V., et al. (2016). Increased Circulating Adiponectin in Response to
923   Thiazolidinediones: Investigating the Role of Bone Marrow Adipose Tissue. Front Endocrinol 7,
924   128.

925 Svensson, P.A., Jernas, M., Sjoholm, K., Hoffmann, J.M., Nilsson, B.E., Hansson, M., and
926   Carlsson, L.M. (2011). Gene expression in human brown adipose tissue. Int. J. Mol. Med. 27,
927   227-232.

928 Thorrez, L., Van Deun, K., Tranchevent, L.C., Van Lommel, L., Engelen, K., Marchal, K., Moreau,
929   Y., Van Mechelen, I., and Schuit, F. (2008). Using ribosomal protein genes as reference: a tale
930   of caution. PLoS One 3, e1854.

931 Tran, M.A., Dang, T.L., and Berlan, M. (1981). Effects of catecholamines on free fatty acid release
932   from bone marrow adipose tissue. J. Lipid Res. 22, 1271-1276.

933 Wang, X., Minze, L.J., and Shi, Z.Z. (2012). Functional imaging of brown fat in mice with 18F-FDG
934   micro-PET/CT. Journal of visualized experiments : JoVE DOI: 10.3791/4060.

935 Williams, M.C., Mirsadraee, S., Dweck, M.R., Weir, N.W., Fletcher, A., Lucatelli, C., MacGillivray,
936   T., Golay, S.K., Cruden, N.L., Henriksen, P.A., et al. (2017). Computed tomography myocardial
937   perfusion vs (15)O-water positron emission tomography and fractional flow reserve. Eur. Radiol.
938   27, 1114-1124.

939 Wu, J., Bostrom, P., Sparks, L.M., Ye, L., Choi, J.H., Giang, A.H., Khandekar, M., Virtanen, K.A.,
940   Nuutila, P., Schaart, G., et al. (2012). Beige adipocytes are a distinct type of thermogenic fat cell
941   in mouse and human. Cell 150, 366-376.

942 Zoch, M.L., Abou, D.S., Clemens, T.L., Thorek, D.L., and Riddle, R.C. (2016). In vivo radiometric
943   analysis of glucose uptake and distribution in mouse bone. Bone Res 4, 16004.

Figure 1

Figure 1 – BMAT is transcriptionally distinct to white, brown and beige adipose tissues. (**A-D)** Transcriptional profiling of gonadal WAT, inguinal WAT, and whole BMAT isolated from the proximal tibia (pBMAT), distal tibia (dBMAT) or radius and ulna (ruBMAT) of two cohorts of rabbits. (A) Principal component analysis of both cohorts. (B-D) Volcano plots (B), GSEA (C) and heatmaps (D) of transcripts differentially expressed between BMAT (dBMAT + ruBMAT) and WAT (iWAT + gWAT) in rabbit cohort 1. **(E)** Transcriptional profiling of adipocytes isolated from femoral BM or subcutaneous WAT of humans. In (B-E), red text indicates differentially expressed transcripts (B) or transcripts/pathways relating to glucose metabolism and/or insulin responsiveness (C-E); *ns* = not significant. **(F)** Representative micrographs of H&E-stained sections of human femoral BM, subcutaneous WAT and trabecular bone; scale bar = 150 µm. **(G)** qPCR of adipocytes isolated from tissues in (F). Data are mean $\pm$ SEM of the following numbers per group: BM Ads, n = 10; WAT Ads, n = 10; Bone Ads, n = 7 (*except IRS1, where n = 2 only*). For each transcript, significant differences between each cell type are indicated by * (P <0.05), ** (P <0.01) or *** (P <0.001). See also Figure S1 and Figure S2.

Figure 2

Figure 2 – Insulin treatment in mice does not induce glucose uptake in BMAT. Insulin-stimulated glucose uptake was assessed by PET/CT. **(A)** Blood glucose post-insulin or vehicle. **(B,D)** Representative PET/CT images of the torso (B) or legs (D) of vehicle- and insulin-treated mice; some FDG uptake into skeletal muscle is evident in the image of the vehicle-treated mouse (D), possibly resulting from physical activity. **(C)** Gamma counts of FDG uptake in iWAT and gWAT, shown as % injected dose per g tissue (%ID/g). **(E)** BMAT analysis by osmium tetroxide staining. BMAT is shown in red in representative μCT reconstructions, and quantified as adipose volume relative to total BM volume (Ad.V/Ma.V). **(F)** FDG uptake in the indicated tissues was determined from PET/CT scans. Data are presented as mean $\pm$ SEM of 5-6 mice (A,C,F) or 5-7 mice (E). Significant differences between control and insulin-treated samples are indicated by * (P <0.05), ** (P <0.01) or *** (P <0.001). In (E), groups do not significantly differ if they share the same letter.

Figure 3

Figure 3 – Cold exposure does not induce glucose uptake or beiging in BMAT. Cold-induced glucose uptake was assessed by PET/CT, as described in Figure S4A. **(A)** Representative PET/CT images of control, acute and chronic cold mice show increased FDG uptake in BAT but not tibiae; some FDG is evident in skeletal muscle of each group. **(B,C)** FDG uptake in the indicated tissues was determined by PMOD analysis of PET/CT scans (B) or gamma counting (C). **(D)** Representative micrographs of H&E-stained tissues, showing that cold exposure decreases lipid content in BAT and promotes beiging of iWAT, but these effects do not occur in BMAT; scale bar = 150 µm. **(E-G)** Cold exposure induces brown and beige adipocyte transcripts in BAT and iWAT, but not in whole bones. *ND* = not detectable. Data in (B-C) and (E-G) are shown as mean ± SEM of 7-8 mice per group. Significant differences between groups are indicated by # (*P* <0.01), * (*P* <0.05), ** (*P* <0.01) or *** (*P* <0.001). See also Figure S3.

Figure 4

Figure 4 – Human BMAT is functionally distinct to BAT and is a major site of basal glucose uptake. **(A)** Representative MRI (HASTE) and CT images from one subject. **(B)** HU distribution of scWAT, BMAT-rich BM (sternum) and BMAT-deficient BM (vertebrae). Data are mean $\pm$ SEM (n = 33). Thresholds diagnostic for BMAT (<115) and RM (115-300) are indicated by dashed lines. **(C)** CT images highlighting BMAT or RM identified using the diagnostic thresholds in (B). Tibiae are shown for completeness but were not present in any other available CT scans. **(D,E)** PET/CT analysis of FDG uptake in *No BAT, Active BAT* and cold-exposed (*Cold)* subjects. Representative PET/CT scans in (D) highlight the BM cavities of the vertebrae and sternum; arrows indicate FDG uptake in supraclavicular BAT. **(F,G)** FDG uptake in bone tissue, RM and BMAT (F), or BMAT and scWAT (G), of room-temperature subjects (*No Bat* and *Active BAT* groups); Fem. = femur, Hum. = humerus, Clav. = clavicle, Vert. = vertebrae, Stern. = sternum. Data are shown as mean $\pm$ SEM (E), paired individual values (F) or box-and-whisker plots (G) of 8 (*No BAT*) or 7 (7 *Active BAT, Cold)* subjects per group. Significant differences between bone, RM and BMAT are indicated by * (P <0.05), ** (P <0.01) or *** (P <0.001). Significant differences between *No BAT, Active BAT* and *Cold* groups are indicated by # (P <0.05) or ### (P <0.001). See also Figure S4.

Figure S1

A

B

Figure S1, Related to Figure 1 – BMAT is transcriptionally distinct to white, brown and beige adipose tissues. Transcriptional profiling of WAT (gonadal + inguinal) vs whole BMAT (dBMAT + ruBMAT) from rabbit cohort 2. **(A)** Volcano plot of differentially expressed transcripts (FDR < 0.05, fold-change > 2). Transcripts characteristic of brown and/or beige adipocytes are labeled. Those with significant differential expression between WAT and BMAT are shown in red; those not differentially expressed are in grey. **(B)** Gene set enrichment analysis (GSEA) highlights lipid metabolism, glucose metabolism and insulin responsiveness as key pathways differentially regulated between WAT and BMAT.

Figure S2

A Isolated adipocytes *(Human cohort 1)*

B Isolated adipocytes *(Human cohort 1)*

C Adipocyte isolation *(Human cohort 2)*

D Isolated adipocytes *(Human cohort 2)*

39

Figure S2, Related to Figure 1 – BM adipocytes in humans are transcriptionally distinct to those from WAT. Transcriptional profiling (A,B) and qPCR analysis (C,D) of adipocytes isolated from the subcutaneous WAT or femoral diaphyseal BM of humans undergoing hip-replacement surgery. **(A,B)** Volcano plots (A) and heat maps (B) are presented as for Figures 1 and S1. **(C,D)** qPCR to validate purity of adipocytes isolated from each tissue (C) and showing that BM adipocytes generally do not have increased expression of brown or beige adipocyte markers (D). Transcript expression was normalized to expression of *IPO8* (C) or *RNA18SN5* (D). Data in (C) are mean $\pm$ SEM of the following numbers per group: BM Ads, n = 8 (*ADIPOQ)* or 9 *(PPARG)*; BM SVF, n = 3 (*ADIPOQ)* or 5 *(PPARG)*; WAT Ads, n = 10 *(ADIPOQ* and *PPARG)*; WAT SVF, n = 5 *(ADIPOQ* and *PPARG)*; Bone Ads and SVF, n = 7 *(PPARG)* or 3 *(ADIPOQ)*. Data in (D) are mean $\pm$ SEM of the following numbers per group: BM Ads, n = 3-10; WAT Ads, n = 6-10; Bone Ads, n = 3-7. For each transcript, significant differences are indicated as for Figure 1.

Figure S3

A

B

C

D

E

F
### BAT

G
iWAT

H
Bone

I
Bone - thermoeutral studies

Figure S3, Related to Figure 3 – Effects of cold exposure on energy homeostasis and gene expression in BAT, iWAT and bone. (A) Protocol for cold exposure and calorimetry studies, as described in the STAR Methods. **(B-H)** Effects of cold exposure on energy expenditure (B), body mass (C), baseline blood glucose (D), 72 h food intake (E) and transcript expression in BAT, iWAT or whole femurs (F-H). In (E), *Acute cold* mice are not shown because they were fasted throughout cold exposure. **(I)** A separate cohort of mice was housed at thermoneutrality, 22 ºC or 4 ºC for 48 h. Expression of BAT or beige cold exposure markers was then determined by qPCR of whole femurs. *ND* = not detectable. In (F-I), transcript expression was normalized to expression of *Rn18s* (F,H,I) or *Ppia* (G); the latter was used for iWAT because in this tissue *Rn18s,* but not *Ppia,* showed significant regulation between the three groups. Data are shown as box-and-whisker plots (B-E) or as mean $\pm$ SEM (F-H) of 7-8 mice per group. In (I), data are mean $\pm$ SEM of 8-10 mice per group. Significant differences between groups are indicated by * (P <0.05), ** (P <0.01) or *** (P <0.001).

Figure S4

Figure S4, Related to Figure 4 – PET/CT for identification and functional analysis of BMAT in humans. (A) ROC analysis to identify HU thresholds to distinguish BMAT-rich (sternum) from BMAT-deficient (vertebrae) regions of BM. **(B)** Quantification of BMAT in CT scans of male and female subjects aged <60 or >60 years. A HU threshold of <115 was used to identify BMAT voxels in BM of the indicated bones, and total BM volume was also determined. The proportion of the BM cavity corresponding to BMAT (Ad.V/Ma.V) was then calculated. Data are shown as box-and-whisker plots of the following numbers of subjects for each group: <60 years, n = 28 (humerus), 9 (femur), or 27 (clavicle, sternum and vertebrae); >60 years, n = 7 for each bone. Significant differences between <60 and >60 groups are indicated by ** (P <0.01). **(C)** Representative coronal PET/CT images of *No BAT, Active BAT* and *Cold* subjects. FDG uptake in BAT is evident in the *Active BAT* and *Cold* subjects (arrows). Femurs were not included in scans of the *Cold* group. **(D)** FDG uptake in bone tissue, RM and BMAT of the indicated bones. Data are shown as mean $\pm$ SEM of 8 (*No BAT*) or 7 (7 *Active BAT, Cold)* subjects per group. Significant differences between these groups *No BAT, Active BAT* and *Cold* groups are indicated by # (P <0.05). **(E)** Subjects were treated with prednisolone or placebo control prior to analysis of FDG uptake by PET/CT. Data are shown as paired individual values for each subject. For each skeletal site, the influence of treatment or tissue (bone, RM, BMAT), and interactions between these, were determined by 2-way ANOVA; P values are shown beneath the graph.